Amgen announces phase 3 FORTITUDE─101 trial of bemarituzumab plus chemotherapy (mFOLFOX6) to treat first line gastric ...
Amgen announced the phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) met its primary endpoint of overall survival (OS) at a pre-specified interim analysis. Bemarituzumab plus chemotherapy demonstrated a …